Hepatitis B virus carriers should be actively treated

        Recently, the Ministry of science and technology of China Medical Biotechnology Association was established by the "hepatitis B treatment research committee" held in Beijing, "hepatitis B virus carriers treatment program expert seminar". The experts pointed out that although the hepatitis B virus carriers with normal liver function, but it has been proved that, only 10% of the carriers of the liver is completely normal, the other 80% have different degrees of liver inflammation and inflammation of the liver, 10% very serious. For many years, there is no good treatment for the treatment of carriers.

        The famous professor Cui Zhenyu liver expert pointed out that: "the carriers with levamisole Liniment (liniment) + triple therapy of hepatitis B vaccine + Pan Shengding, preliminary observation, cost only 100 yuan per month, for Chinese conditions. In addition, it is Su Sheng professor of HBV specific active immunotherapy (commonly known as therapeutic hepatitis B vaccine), there are a lot of foreign reports, preliminary clinical researches also prove that HBV specific active immunotherapy can break the immune tolerance of HBV, and has a certain effect on HBsAg Yin, this is a very big breakthrough. However, the above research is not perfect, need to be further verified. These programs will conduct clinical trials in Beijing, Tzu Chi clinic liver disease treatment center."